The Latest: Indian-made vaccine works against all variants

NEW DELHI — Indian company Bharat Biotech says its late-stage testing of a COVID-19 vaccine has shown an overall efficacy of 77.8% and effectiveness against all variants.

The company in a statement says it is now in discussions with the World Health Organization to obtain emergency use listing for its vaccine, marketed as COVAXIN.

The results set at rest questions raised by health experts over Bharat Biotech’s vaccine when it was given emergency use authorization by the Indian government in January. They felt that the company didn’t have enough clinical trials, making it almost impossible for the firm to have analyzed and submitted data showing that its shots are effective in preventing illness from the coronavirus.

The company says the vaccine has already received emergency use authorizations in 16 countries including India, the Philippines, Iran and Mexico. Millions of Indian also have been inoculated with the same vaccine.

It says the late-stage trial showed the vaccine was 93.4% effective against severe symptomatic COVID-19 and showed effectiveness of 77.8% against symptomatic COVID-19. The data also demonstrated 65.2% protection against the delta variant, first identified in India.

___

MORE ON THE PANDEMIC

— Europe in vaccination race against COVID-19′s delta variant

— Indonesia caught between surge and slow vaccine rollout

— Thai virus surge prompts concern over ICUs, vaccine supply

— Some Venezuelans have gotten a shot in the arm thanks to a gift of Cuban-developed COVID-19 vaccines, bringing relief to some residents while simultaneously deepening the mystery around the country’s donation-dependent vaccination campaign.

— One Missouri hospital official is telling anyone making disparaging remarks about the...